Weixuan Yang

Mr. Weixuan Yang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Laboratory Investigation
Verified
Journal Article
Closed access
JTJia-Wei Tang
Jia-Wei Tang
FLFen Li
Fen Li
XLXin Liu
Xin Liu
JWJin-Ting Wang
Jin-Ting Wang
XXXue-Song Xiong
Xue-Song Xiong
LWLiang Wang
Liang Wang

18 September 2024 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
FLFen Li
Fen Li
YSYu-Ting Si
Yu-Ting Si
JTJia-Wei Tang
Jia-Wei Tang
ZUZeeshan Umar
Zeeshan Umar
XXXue-Song Xiong
Xue-Song Xiong
LWLiang Wang
Liang Wang
WHO classified Helicobacter pylori as a Group I carcinogen for gastric cancer as early as 1994. However, despite the high prevalence of H. pylori infection, only about 3 % of infected individuals eventually develop gastric cancer, with the highly virulent H. pylori strains expressing cytotoxin-associated protein (CagA) and vacuolating cytotoxin (VacA) being critical factors in gastric carcinogenesis. It is well known that H. pylori infection is divided into two types in terms of the presence and absence of CagA and VacA toxins in serum, that is, carcinogenic Type I infection (CagA+/VacA+, CagA+/VacA-, CagA-/VacA+) and non-carcinogenic Type II infection (CagA-/VacA-). Currently, detecting the two carcinogenic toxins in active modes is mainly done by diagnosing their serological antibodies. However, the method is restricted by expensive reagents and intricate procedures. Therefore, establishing a rapid, accurate, and cost-effective way for serological profiling of carcinogenic H. pylori infection holds significant implications for effectively guiding H. pylori eradication and gastric cancer prevention. In this study, we developed a novel method by combining surface-enhanced Raman spectroscopy with the deep learning algorithm convolutional neural network to create a model for distinguishing between serum samples with Type I and Type II H. pylori infections. This method holds the potential to facilitate rapid screening of H. pylori infections with high risks of carcinogenesis at the population level, which can have long-term benefits in reducing gastric cancer incidence when used for guiding the eradication of H. pylori infections.

26 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
QSQinhao Shen
Qinhao Shen
SWShuai Wang
Shuai Wang
KWKeyan Wu
Keyan Wu
LWLiuhui Wang
Liuhui Wang
WGWeijuan Gong
Weijuan Gong
WYWeixuan Yang
Weixuan Yang
Introduction: Macrophage activation is closely associated with Acute pancreatitis (AP). We screened and found that Growth factor receptor bound protein 2 (Grb2) is highly expressed in macrophages during AP. However, the relationship between Grb2 and AP is still poorly understood. In this study, we explored the role of Grb2 in AP.Methods: We screened for gene affecting macrophage activation in AP by combining transcriptomics with Single-cell RNA-sequence analysis. Next, the expression of Grb2 in M1/M2 macrophage activation was detected by Single-cell RNA-sequence analysis and western blot. Furthermore, the effect of Grb2 on M1/M2 macrophage activation was detected by flow cytometry. The severity of AP was assessed by histological analysis, serum amylase, serum lipase and serum inflammatory factors in vivo. NOD-like receptor thermal protein domain associated protein 3 (Nlrp3) and Nuclear factor kappa-B (NF-kB) signaling pathways were also evaluated.Results: Grb2 is mainly expressed in macrophages of pancreas in AP and up-regulated in M1 macrophage activation. Inhibiting Grb2 could alleviate AP by preventing M1 macrophage activation through down-regulating Nlrp3 and NF-κB.Discussion: Inhibition of Grb2 can effectively prevent M1 macrophage activation and alleviate AP. Grb2 may potentially be an effective target of macrophage activation for the treatment of AP.

10 October 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
JZJingjing Zhang
Jingjing Zhang
PLPin Li
Pin Li
XXXingmeng Xu
Xingmeng Xu
YHYishao He
Yishao He
CYChenchen Yuan
Chenchen Yuan
WYWeixuan Yang
Weixuan Yang

Verified
Journal Article
Open access
PDF file
LCLingju Chu
Lingju Chu
LZLei Zhang
Lei Zhang
XLXinyi Liu
Xinyi Liu
QZQingtian Zhu
Qingtian Zhu
小董小武 董
小武 董
YWYaodong Wang
Yaodong Wang
Acute pancreatitis (AP) is a severe inflammatory disorder with limited therapeutic options. Novel bile acids have emerged as potent immunomodulators, but the function of norcholic acid (NorCA) previously remained unknown. In this study, we identified NorCA’s role as a novel immunomodulator that alleviates acute pancreatitis through peroxisome proliferator-activated receptor α (PPARα)-mediated macrophage reprogramming and efferocytosis. Targeted metabolomics was performed on serum from patients with AP and caerulein-induced AP mice. The functional role and mechanism of NorCA were investigated using flow cytometry, immunofluorescence, efferocytosis assays, and network pharmacology, both in vitro and in vivo. Our findings indicate that NorCA levels were significantly elevated in both patients and mice with AP, correlating with disease severity and complications. NorCA treatment markedly reduced serum amylase/lipase and pancreatic histopathological damage in AP mice. Mechanistically, NorCA promoted M1-to-M2 macrophage reprogramming and enhanced efferocytosis of apoptotic cells. These effects were dependent on PPARα activation, as demonstrated by siRNA silencing and pharmacological antagonism. These findings position NorCA as a promising therapeutic candidate and severity-associated metabolite in AP.

27 October 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
KSKaifeng Sun
Kaifeng Sun
JXJingjing Xia
Jingjing Xia
JWJinting Wang
Jinting Wang
LHLe He
Le He
WYWeixuan Yang
Weixuan Yang
HWHonggang Wang
Honggang Wang
Quantitative urea breath-test (UBT) values are routinely reported, but their systemic significance beyond Helicobacter pylori positivity remains uncertain. We analyzed 21,195 adults from two health-check cohorts, distinguishing test positivity from delta-over-baseline (DOB) variation among positive participants. We used adjusted models, cohort comparisons and false discovery rate (FDR) correction, with public serological and gastric expression datasets providing exploratory comparisons. Overall, 5484 participants tested positive. In pooled analyses, positivity was associated with higher white blood cell counts (adjusted difference, 0.302 × 109/L; 95% confidence interval, 0.249–0.355). Neutrophil counts were also higher (0.199 × 109/L; 0.164–0.234), whereas high-density lipoprotein (HDL) cholesterol was lower (−0.029 mmol/L; −0.038 to −0.019). The HDL association was not clearly replicated in Cohort 2. Associations within the positive range varied with model specification and were not consistently replicated. Additional adjustment for smoking and socioeconomic factors attenuated the leukocyte association in the serological data. Among 3670 positive adults with clinical records, ordinal associations with coded fatty liver, diabetes or hypertension were not FDR significant, and estimates remained imprecise. Gastric expression data supported local inflammation but did not establish a mechanism linking infection to circulating HDL. DOB within the positive range showed no consistent systemic gradient. Residual confounding and imprecise clinical estimates limit interpretation; nonsignificant results do not establish equivalence. These findings neither validate DOB as a measure of bacterial burden nor establish its incremental predictive value. They provide insufficient evidence to use DOB magnitude for metabolic risk assessment or treatment prioritization.